Home LiteratureArticle Details
PMID: 26026090 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.

Anticancer research ·Vol. 35 ·No. 6 ·2015-06-00 ·页码 3307-16

Takenokuchi M, Miyamoto K, Saigo K, Taniguchi T

Abstract

The success of proteasome inhibitors in therapy of multiple myeloma has led to their use for other malignancies. For the proteasome inhibitor bortezomib, combination therapies with histone deacetylase inhibitors, which up-regulate ubiquitin-proteasome system (UPS)-related enzymes, produce a beneficial effect. However, the mechanisms underlying the effect of bortezomib are not completely understood. We hypothesized that bortezomib causes excessive accumulation of aberrant proteins, which augments endoplasmic reticulum (ER) stress, leading to death of malignant cells. The NB4 cell line established from a patient with acute promyelocytic leukemia (APL) expressing the promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) fusion protein was used to assess changes in cell viability and apoptosis caused by bortezomib, as well as alterations in PML-RARA and UPS-related enzymes via western blotting and immunoprecipitation assays. Bortezomib time- and dose-dependently reduced cell viability and induced apoptosis. Bortezomib significantly increased the abundance of ubiquitinated-PML-RARA (Ub-PML-RARA), ubiquitin-conjugating human enzyme 8 (UbcH8), and Ub-UbcH8, indicating that UbcH8 is the E2 ubiquitin-conjugating enzyme for PML-RARA. Moreover, UbcH8 abundance was dose-dependently increased in the culture supernatant of bortezomib-treated cells. UbcH8 may have a utility as a biomarker of treatment response to bortezomib in patients with APL. Furthermore, bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA augmenting ER stress and leading to APL cell death. The study provides a rationale for incorporating proteasome inhibitors in the treatment of diseases expressing aberrant proteins. Furthermore, monitoring of UPS-related enzymes might have use in predicting the treatment response to proteasome inhibitors and in assessing their therapeutic effects.

Keywords
ER stress PML–RARA Proteasome inhibitor ubiquitin-proteasome system
MeSH 主题词
Boronic Acids/administration & dosage,metabolism Bortezomib Cell Death/drug effects Cell Line, Tumor Endoplasmic Reticulum Stress/drug effects,genetics Humans Leukemia, Promyelocytic, Acute/drug therapy,genetics,pathology Oncogene Proteins, Fusion/biosynthesis,genetics Pyrazines/administration & dosage,metabolism Transcriptional Activation/drug effects Ubiquitin-Conjugating Enzymes/genetics
化学物质
Boronic Acids Oncogene Proteins, Fusion Pyrazines promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Bortezomib UBE2L6 protein, human Ubiquitin-Conjugating Enzymes
作者与单位
共 4 位作者,点击展开单位 / ORCID
Takenokuchi Mariko
Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan [email protected].
Miyamoto Kazuhide
Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan.
Saigo Katsuyasu
Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan.
Taniguchi Taizo
Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan.
Article Info
Journal
Anticancer research
Abbr.
Anticancer Res
ISSN
1791-7530
Corresponding email
Published
2015-06-00
页码
3307-16
Language
English
Country/Region
Greece
NLM ID
8102988
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]